# Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

> **NCT02131662** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 309 (actual)

## Conditions studied

- Leiomyoma

## Interventions

- **DRUG:** BAY1002670
- **DRUG:** BAY1002670
- **DRUG:** BAY1002670
- **DRUG:** BAY1002670
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02131662
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-15
- **Primary completion:** 2016-05-04
- **Final completion:** 2016-05-04
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2017-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02131662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02131662, "Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02131662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*